Wei Yang

ORCID: 0000-0003-2977-6681
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pleural and Pulmonary Diseases
  • Treatment of Major Depression
  • Lung Cancer Diagnosis and Treatment
  • Mesenchymal stem cell research
  • Epilepsy research and treatment
  • Bladder and Urothelial Cancer Treatments
  • Pancreatic and Hepatic Oncology Research
  • Inflammatory Biomarkers in Disease Prognosis
  • Lung Cancer Treatments and Mutations
  • Pharmacological Effects and Toxicity Studies
  • Occupational and environmental lung diseases
  • Soft tissue tumor case studies
  • Gastric Cancer Management and Outcomes
  • Transplantation: Methods and Outcomes
  • Hematopoietic Stem Cell Transplantation
  • Cancer Immunotherapy and Biomarkers
  • Neuroscience and Neuropharmacology Research

Changzhi Medical College
2019-2025

Shanxi Medical University
2022

Tibet Autonomous Region People's Hospital
2018

390 Background: Combining epigenetic modulator with PD-1 inhibitor may enhance treatment outcomes in cancer patients. This study aimed to evaluate the efficacy and safety of drug decitabine, sintilimab (a inhibitor), chemotherapy gastric cancer. Methods: In this single-arm, exploratory phase II trial, patients HER2-negative, locally advanced or metastatic gastroesophageal junction (G/GEJ) adenocarcinoma were enrolled between August 12, 2021, October 22, 2022. Treatment included low-dose...

10.1200/jco.2025.43.4_suppl.390 article EN Journal of Clinical Oncology 2025-01-27

Background This study aimed to evaluate the predictive value of presurgical factors for psychiatric disorders (PD) in refractory temporal lobe epilepsy and mesial sclerosis (TLE‐MTS) patients underwent cortico‐amygdalohippocampectomy (CAH). Methods A total 98 TLE‐MTS CAH were consecutively enrolled this cohort study. Several recorded, such as married status, employment highest education, disease duration, family history epilepsy, disorganized VEEG background activity. Results There 17...

10.1002/jcla.22724 article EN cc-by Journal of Clinical Laboratory Analysis 2018-12-05

3147 Background: Immune checkpoint inhibitors have opened a new chapter in cancer therapy, but the incidence of irAEs caused by them is high, and severe can be fatal. The current research on almost focused early predictions, there lack near-term predictions (the cycle before occurrence irAEs). Absolute eosinophil count (EO#) has been reported to associated with immune-related pneumonia, its association other systemic requires further exploration. aim this study was explore predictive value...

10.1200/jco.2022.40.16_suppl.3147 article EN Journal of Clinical Oncology 2022-06-01

Acquired severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome. Immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the main treatments for acquired SAA. Matched sibling donor (MSD)-hematopoietic (HSCT) best treatment SAA patients who younger than 40 years old. Outcomes of unrelated (URD)-HSCT, haploidentical (haplo-HSCT) umbilical cord blood (UCBT) have improved in recent decade, provide more options with respect...

10.3760/cma.j.issn.1673-419x.2019.05.015 article EN Guoji shuxue ji xueyexue zazhi 2019-09-20
Coming Soon ...